Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Active Controlled, Phase I/ II Clinical Trial to Assess the Immunogenicity, Safety, and Tolerability of NBP615 Vaccine in Healthy Female Participants Aged 19 to 26 Years and Adolescent Aged 9 to 13 Years

NCT04453241 is registered in ClinicalTrials.gov with SK Bioscience Co., Ltd. as lead sponsor.

NCT NCT04453241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04453241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Active Controlled, Phase I/ II Clinical Trial to Assess the Immunogenicity, Safety, and Tolerability of NBP615 Vaccine in Healthy Female Participants Aged 19 to 26 Years and Adolescent Aged 9 to 13 Years
Lead sponsor
SK Bioscience Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
December 22, 2018
Completion date
December 30, 2019
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer